Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

BUY
$73.27 - $83.09 $6,594 - $7,478
90 Added 0.56%
16,235 $1.32 Million
Q3 2023

Nov 15, 2023

BUY
$73.94 - $80.67 $45,694 - $49,854
618 Added 3.98%
16,145 $1.21 Million
Q2 2023

Sep 07, 2023

BUY
$76.01 - $86.7 $19,230 - $21,935
253 Added 1.66%
15,527 $1.2 Million
Q2 2023

Aug 11, 2023

BUY
$76.01 - $86.7 $76,998 - $87,827
1,013 Added 6.98%
15,527 $1.2 Million
Q1 2023

Sep 07, 2023

SELL
$77.31 - $88.08 $102,976 - $117,322
-1,332 Reduced 8.02%
15,274 $1.27 Million
Q1 2023

Sep 01, 2023

SELL
$77.31 - $88.08 $102,976 - $117,322
-1,332 Reduced 8.02%
15,274 $1.27 Million
Q1 2023

May 10, 2023

BUY
$77.31 - $88.08 $4,561 - $5,196
59 Added 0.41%
14,514 $1.2 Million
Q4 2022

Sep 07, 2023

BUY
$62.32 - $89.47 $67,243 - $96,538
1,079 Added 6.95%
16,606 $1.43 Million
Q4 2022

Sep 01, 2023

BUY
$62.32 - $89.47 $67,243 - $96,538
1,079 Added 6.95%
16,606 $1.43 Million
Q4 2022

Feb 08, 2023

BUY
$62.32 - $89.47 $4,549 - $6,531
73 Added 0.51%
14,455 $1.24 Million
Q3 2022

Nov 14, 2022

SELL
$59.54 - $68.01 $1,845 - $2,108
-31 Reduced 0.22%
14,382 $887,000
Q2 2022

Aug 01, 2022

SELL
$57.72 - $65.01 $253,968 - $286,044
-4,400 Reduced 23.39%
14,413 $891,000
Q1 2022

May 11, 2022

BUY
$57.92 - $72.58 $165,361 - $207,215
2,855 Added 17.89%
18,813 $1.22 Million
Q4 2021

Feb 14, 2022

SELL
$64.88 - $73.64 $1,881 - $2,135
-29 Reduced 0.18%
15,958 $1.16 Million
Q3 2021

Oct 21, 2021

SELL
$67.69 - $73.03 $229,604 - $247,717
-3,392 Reduced 17.5%
15,987 $1.12 Million
Q2 2021

Jul 23, 2021

BUY
$63.47 - $69.35 $2,919 - $3,190
46 Added 0.24%
19,379 $1.33 Million
Q1 2021

Apr 23, 2021

SELL
$60.0 - $68.46 $31,380 - $35,804
-523 Reduced 2.63%
19,333 $1.25 Million
Q4 2020

Feb 01, 2021

SELL
$56.65 - $64.55 $57,896 - $65,970
-1,022 Reduced 4.9%
19,856 $1.16 Million
Q3 2020

Oct 21, 2020

BUY
$62.1 - $78.08 $36,763 - $46,223
592 Added 2.92%
20,878 $1.32 Million
Q2 2020

Jul 23, 2020

SELL
$72.34 - $84.0 $11.2 Million - $13 Million
-154,468 Reduced 88.39%
20,286 $1.56 Million
Q1 2020

Apr 16, 2020

BUY
$62.63 - $80.22 $10 Million - $12.9 Million
160,303 Added 1109.29%
174,754 $13.1 Million
Q4 2019

Jan 27, 2020

BUY
$61.62 - $67.78 $2,279 - $2,507
37 Added 0.26%
14,451 $939,000
Q3 2019

Oct 24, 2019

SELL
$62.51 - $69.0 $91,452 - $100,947
-1,463 Reduced 9.21%
14,414 $914,000
Q2 2019

Jul 22, 2019

BUY
$61.87 - $69.38 $13,487 - $15,124
218 Added 1.39%
15,877 $1.07 Million
Q1 2019

Apr 15, 2019

BUY
$62.53 - $70.05 $5,940 - $6,654
95 Added 0.61%
15,659 $1.02 Million
Q4 2018

Jan 16, 2019

SELL
$60.54 - $79.0 $57,210 - $74,655
-945 Reduced 5.72%
15,564 $974,000
Q3 2018

Oct 23, 2018

BUY
$71.28 - $78.92 $1,995 - $2,209
28 Added 0.17%
16,509 $1.28 Million
Q2 2018

Jul 20, 2018

BUY
$64.88 - $75.68 $4,087 - $4,767
63 Added 0.38%
16,481 $1.17 Million
Q4 2017

Jan 23, 2018

SELL
$71.15 - $83.52 $75,774 - $88,948
-1,065 Reduced 6.09%
16,418 $1.18 Million
Q3 2017

Oct 16, 2017

BUY
$72.11 - $85.47 $1.26 Million - $1.49 Million
17,483
17,483 $1.42 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Jag Capital Management, LLC Portfolio

Follow Jag Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jag Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jag Capital Management, LLC with notifications on news.